Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Prostate Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 39 articles:
HTML format



Single Articles


    May 2025
  1. DEV H, Linch M, Narahari K, Milne-Clark T, et al
    Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib +/- Degarelix in Primary Prostate Cancer.
    Clin Cancer Res. 2025 May 13:OF1-OF11. doi: 10.1158/1078-0432.CCR-24-1304.
    PubMed     Abstract available


  2. ARAFA AT, Yadav S, Marshall CH, Mauer E, et al
    Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality.
    Clin Cancer Res. 2025;31:1730-1745.
    PubMed     Abstract available


    April 2025
  3. WERNECK GOMES H, Lister NL, Keerthikumar S, Niranjan B, et al
    p-AKT protein expression predicts response to AKT inhibitor combined with docetaxel therapy in adenocarcinoma and neuroendocrine prostate cancer.
    Clin Cancer Res. 2025 Apr 25. doi: 10.1158/1078-0432.CCR-24-3848.
    PubMed     Abstract available


  4. SHAH K, Secrest MH, Zhou W, Wang S, et al
    Clinical Context Shapes the Relationship Between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.
    Clin Cancer Res. 2025 Apr 14. doi: 10.1158/1078-0432.CCR-24-1812.
    PubMed     Abstract available


  5. KISHAN AU, McGreevy K, Valle L, Steinberg M, et al
    Validation and Derivation of MicroRNA-based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.
    Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3951.
    PubMed     Abstract available


    March 2025
  6. MCNEVIN CS, Keogh A, Mohammed Nur M, McGovern B, et al
    Prevalence of Mismatch Repair Deficiency in Primary Prostate Cancer in a Large Prospective Cohort.
    Clin Cancer Res. 2025 Mar 19:OF1-OF8. doi: 10.1158/1078-0432.CCR-24-1210.
    PubMed     Abstract available


  7. ZHANG L, Teng PC, Cavassani KA, Wang J, et al
    Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer.
    Clin Cancer Res. 2025 Mar 10. doi: 10.1158/1078-0432.CCR-24-3660.
    PubMed     Abstract available


  8. HWANG J, Likasitwatanakul P, Deshmukh SK, Wu S, et al
    Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes.
    Clin Cancer Res. 2025;31:936-948.
    PubMed     Abstract available


    February 2025
  9. BJARTELL A, Krzyzanowska A, Liu VYT, Tierney M, et al
    Validation of a digital pathology-based multimodal artificial intelligence biomarker in a prospective, real-world prostate cancer cohort treated with prostatectomy.
    Clin Cancer Res. 2025 Feb 21. doi: 10.1158/1078-0432.CCR-24-3656.
    PubMed     Abstract available


  10. GALSKY MD, Autio KA, Cabanski CR, Wentzel K, et al
    Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2025 Feb 18. doi: 10.1158/1078-0432.CCR-24-3693.
    PubMed     Abstract available


  11. BIDKAR AP, Peter R, Wadhwa A, Bobba KN, et al
    Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.
    Clin Cancer Res. 2025 Feb 13. doi: 10.1158/1078-0432.CCR-24-2850.
    PubMed     Abstract available


    January 2025
  12. CHIU CL, Zhang D, Zhao H, Wei Y, et al
    Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
    Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028.
    PubMed     Abstract available


  13. ANDREWS J, Kim Y, Horjeti E, Arafa A, et al
    PSMA+ Extracellular Vesicles are a Biomarker for SABR in Oligorecurrent Prostate Cancer Analysis from the STOMP-like and ORIOLE trial cohorts.
    Clin Cancer Res. 2025 Jan 16. doi: 10.1158/1078-0432.CCR-24-3027.
    PubMed     Abstract available


  14. WELTI J, Bogdan D, Figueiredo I, Coleman I, et al
    NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth.
    Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2386.
    PubMed     Abstract available


    November 2024
  15. HAFFNER MC, Morris MJ, Ding CC, Sayar E, et al
    Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.
    Clin Cancer Res. 2024 Nov 26. doi: 10.1158/1078-0432.CCR-24-2061.
    PubMed     Abstract available


  16. WINQUIST E, Hotte SJ, Chi K, Sridhar S, et al
    Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-1612.
    PubMed     Abstract available


  17. NAWFAL R, El Hajj Chehade R, Berchuck JE
    Unearthing a prostate cancer cfDNA signature that "stems" from AR alterations.
    Clin Cancer Res. 2024 Nov 4. doi: 10.1158/1078-0432.CCR-24-2849.
    PubMed     Abstract available


    October 2024
  18. STOPSACK KH, Vijai J, Conry M, Berchuck JE, et al
    Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer.
    Clin Cancer Res. 2024 Oct 25. doi: 10.1158/1078-0432.CCR-24-2483.
    PubMed     Abstract available


    September 2024
  19. ISAACSSON VELHO P, Bastos DA, Saint'ana PT, Rigatti B, et al
    Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects.
    Clin Cancer Res. 2024 Sep 27. doi: 10.1158/1078-0432.CCR-24-1595.
    PubMed     Abstract available


  20. CHOU J, Robinson TM, Egusa EA, Lodha R, et al
    Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors.
    Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-23-3785.
    PubMed     Abstract available


  21. JENSEN JL, Bobek O, Chan ICC, Miller BC, et al
    Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
    Clin Cancer Res. 2024 Sep 17:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0803.
    PubMed     Abstract available


  22. DALLOS MC, Obradovic AZ, McCann P, Chowdhury N, et al
    Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
    Clin Cancer Res. 2024 Sep 13. doi: 10.1158/1078-0432.CCR-24-0060.
    PubMed     Abstract available


    August 2024
  23. CHAUHAN PS, Alahi I, Sinha S, Ledet EM, et al
    Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in lethal prostate cancer.
    Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-1658.
    PubMed     Abstract available


  24. HUSSAIN M, Kocherginsky M, Agarwal N, Adra N, et al
    Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
    Clin Cancer Res. 2024 Aug 8. doi: 10.1158/1078-0432.CCR-24-1402.
    PubMed     Abstract available


  25. NGUYEN CB, Reimers MA, Perera C, Abida W, et al
    Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
    Clin Cancer Res. 2024;30:3200-3210.
    PubMed     Abstract available


    July 2024
  26. SWEENEY CJ, Petry R, Xu C, Childress M, et al
    Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Jul 11. doi: 10.1158/1078-0432.CCR-24-1096.
    PubMed     Abstract available


  27. LENIS AT, Ravichandran V, Brown S, Alam SM, et al
    Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
    Clin Cancer Res. 2024 Jul 1. doi: 10.1158/1078-0432.CCR-23-3403.
    PubMed     Abstract available


    April 2024
  28. APARICIO AM, Tidwell RSS, Yadav SS, Chen JS, et al
    A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Apr 29. doi: 10.1158/1078-0432.CCR-23-3740.
    PubMed     Abstract available


  29. ARCHER S, Brailey PM, Song M, Bartlett PD, et al
    CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.
    Clin Cancer Res. 2024;30:1595-1606.
    PubMed     Abstract available


  30. SCHATZ CA, Zitzmann-Kolbe S, Moen I, Klotz M, et al
    Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
    Clin Cancer Res. 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746.
    PubMed     Abstract available


  31. CHO H, Byun SS, Son NH, Chung JI, et al
    Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
    Clin Cancer Res. 2024 Apr 8:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-3083.
    PubMed     Abstract available


    March 2024
  32. DESAI KB, Serritella AV, Stadler WM, O'Donnell PH, et al
    A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
    Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3636.
    PubMed     Abstract available


  33. AGARWAL N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, et al
    A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
    Clin Cancer Res. 2024 Mar 21. doi: 10.1158/1078-0432.CCR-23-3436.
    PubMed     Abstract available


  34. ANSELMINO N, Labanca E, Shepherd PDA, Dong J, et al
    Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series.
    Clin Cancer Res. 2024 Mar 15. doi: 10.1158/1078-0432.CCR-23-2438.
    PubMed     Abstract available


    February 2024
  35. VELLKY JE, Kirkpatrick BJ, Gutgesell LC, Morales M, et al
    ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature.
    Clin Cancer Res. 2024 Feb 2. doi: 10.1158/1078-0432.CCR-23-2161.
    PubMed     Abstract available


  36. DORFF T, Horvath LG, Autio K, Bernard-Tessier A, et al
    A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-2978.
    PubMed     Abstract available


    January 2024
  37. HALABI S, Guo S, Park JJ, Nanus DM, et al
    The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-3017.
    PubMed     Abstract available


  38. ABIDA W, Hahn AW, Shore N, Agarwal N, et al
    Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing on Enzalutamide.
    Clin Cancer Res. 2024 Jan 16. doi: 10.1158/1078-0432.CCR-23-3508.
    PubMed     Abstract available


    September 2023
  39. CHAUDAGAR K, Hieromnimon HM, Kelley A, Labadie B, et al
    Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.
    Clin Cancer Res. 2023 Sep 18. doi: 10.1158/1078-0432.CCR-23-1441.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.